{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T20:50:55Z","timestamp":1792615855332,"version":"4.5.0"},"reference-count":31,"publisher":"The Endocrine Society","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context:<\/jats:title>\n                    <jats:p>The p.Leu167del mutation in the APOE gene has been associated with hyperlipidemia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>Our objective was to determine the frequency of p.Leu167del mutation in APOE gene in subjects with autosomal dominant hypercholesterolemia (ADH) in whom LDLR, APOB, and PCSK9 mutations had been excluded and to identify the mechanisms by which this mutant apo E causes hypercholesterolemia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>The APOE gene was analyzed in a case-control study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting:<\/jats:title>\n                    <jats:p>The study was conducted at a University Hospital Lipid Clinic.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients or Other Participants:<\/jats:title>\n                    <jats:p>Two groups (ADH, 288 patients; control, 220 normolipidemic subjects) were included.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Intervention:<\/jats:title>\n                    <jats:p>We performed sequencing of APOE gene and proteomic and cellular experiments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Outcome Measure:<\/jats:title>\n                    <jats:p>To determine the frequency of the p.Leu167del mutation and the mechanism by which it causes hypercholesterolemia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>In the ADH group, nine subjects (3.1%) were carriers of the APOE c.500_502delTCC, p.Leu167del mutation, cosegregating with hypercholesterolemia in studied families. Proteomic quantification of wild-type and mutant apo E in very low-density lipoprotein (VLDL) from carrier subjects revealed that apo E3 is almost a 5-fold increase compared to mutant apo E. Cultured cell studies revealed that VLDL from mutation carriers had a significantly higher uptake by HepG2 and THP-1 cells compared to VLDL from subjects with E3\/E3 or E2\/E2 genotypes. Transcriptional down-regulation of LDLR was also confirmed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>p.Leu167del mutation in APOE gene is the cause of hypercholesterolemia in the 3.1% of our ADH subjects without LDLR, APOB, and PCSK9 mutations. The mechanism by which this mutation is associated to ADH is that VLDL carrying the mutant apo E produces LDLR down-regulation, thereby raising plasma low-density lipoprotein cholesterol levels.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/jc.2015-3874","type":"journal-article","created":{"date-parts":[[2016,3,25]],"date-time":"2016-03-25T13:02:37Z","timestamp":1458910957000},"page":"2113-2121","source":"Crossref","is-referenced-by-count":100,"title":["The p.Leu167del Mutation in APOE Gene Causes Autosomal Dominant Hypercholesterolemia by Down-regulation of LDL Receptor Expression in Hepatocytes"],"prefix":"10.1210","volume":"101","author":[{"given":"Ana","family":"Cenarro","sequence":"first","affiliation":[{"name":"Unidad Cl\u00ednica y de Investigaci\u00f3n en L\u00edpidos y Arteriosclerosis (A.C., I.d.C.-O., A.M.B., R.M.-G., F.C.), Laboratorio de Investigaci\u00f3n Molecular, Hospital Universitario Miguel Servet, Instituto de Investigaci\u00f3n Sanitaria Arag\u00f3n, Zaragoza, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aitor","family":"Etxebarria","sequence":"additional","affiliation":[{"name":"Unidad de Biof\u00edsica (Consejo Superior de Investigaciones Cient\u00edficas, Universidad del Pa\u00eds Vasco\/Euskal Herriko Unibertsitatea) and Departamento de Bioqu\u00edmica y Biolog\u00eda Molecular (A.E., A.B.-V., H.O., C.M.), Universidad del Pa\u00eds Vasco\/Euskal Herriko Unibertsitatea, Bilbao, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"de Castro-Or\u00f3s","sequence":"additional","affiliation":[{"name":"Unidad Cl\u00ednica y de Investigaci\u00f3n en L\u00edpidos y Arteriosclerosis (A.C., I.d.C.-O., A.M.B., R.M.-G., F.C.), Laboratorio de Investigaci\u00f3n Molecular, Hospital Universitario Miguel Servet, Instituto de Investigaci\u00f3n Sanitaria Arag\u00f3n, Zaragoza, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Stef","sequence":"additional","affiliation":[{"name":"Progenika Biopharma (M.S., L.P.), a Grifols Company, Derio, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana M.","family":"Bea","sequence":"additional","affiliation":[{"name":"Unidad Cl\u00ednica y de Investigaci\u00f3n en L\u00edpidos y Arteriosclerosis (A.C., I.d.C.-O., A.M.B., R.M.-G., F.C.), Laboratorio de Investigaci\u00f3n Molecular, Hospital Universitario Miguel Servet, Instituto de Investigaci\u00f3n Sanitaria Arag\u00f3n, Zaragoza, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lourdes","family":"Palacios","sequence":"additional","affiliation":[{"name":"Progenika Biopharma (M.S., L.P.), a Grifols Company, Derio, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roc\u00edo","family":"Mateo-Gallego","sequence":"additional","affiliation":[{"name":"Unidad Cl\u00ednica y de Investigaci\u00f3n en L\u00edpidos y Arteriosclerosis (A.C., I.d.C.-O., A.M.B., R.M.-G., F.C.), Laboratorio de Investigaci\u00f3n Molecular, Hospital Universitario Miguel Servet, Instituto de Investigaci\u00f3n Sanitaria Arag\u00f3n, Zaragoza, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asier","family":"Benito-Vicente","sequence":"additional","affiliation":[{"name":"Unidad de Biof\u00edsica (Consejo Superior de Investigaciones Cient\u00edficas, Universidad del Pa\u00eds Vasco\/Euskal Herriko Unibertsitatea) and Departamento de Bioqu\u00edmica y Biolog\u00eda Molecular (A.E., A.B.-V., H.O., C.M.), Universidad del Pa\u00eds Vasco\/Euskal Herriko Unibertsitatea, Bilbao, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Ostolaza","sequence":"additional","affiliation":[{"name":"Unidad de Biof\u00edsica (Consejo Superior de Investigaciones Cient\u00edficas, Universidad del Pa\u00eds Vasco\/Euskal Herriko Unibertsitatea) and Departamento de Bioqu\u00edmica y Biolog\u00eda Molecular (A.E., A.B.-V., H.O., C.M.), Universidad del Pa\u00eds Vasco\/Euskal Herriko Unibertsitatea, Bilbao, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Tejedor","sequence":"additional","affiliation":[{"name":"Departamento de Anatom\u00eda (T.T.), Embriolog\u00eda y Gen\u00e9tica, Universidad de Zaragoza, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9sar","family":"Mart\u00edn","sequence":"additional","affiliation":[{"name":"Unidad de Biof\u00edsica (Consejo Superior de Investigaciones Cient\u00edficas, Universidad del Pa\u00eds Vasco\/Euskal Herriko Unibertsitatea) and Departamento de Bioqu\u00edmica y Biolog\u00eda Molecular (A.E., A.B.-V., H.O., C.M.), Universidad del Pa\u00eds Vasco\/Euskal Herriko Unibertsitatea, Bilbao, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Civeira","sequence":"additional","affiliation":[{"name":"Unidad Cl\u00ednica y de Investigaci\u00f3n en L\u00edpidos y Arteriosclerosis (A.C., I.d.C.-O., A.M.B., R.M.-G., F.C.), Laboratorio de Investigaci\u00f3n Molecular, Hospital Universitario Miguel Servet, Instituto de Investigaci\u00f3n Sanitaria Arag\u00f3n, Zaragoza, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","reference":[{"key":"2020071614231287700_B1","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.atherosclerosis.2003.11.010","article-title":"International Panel on Management of Familial Hypercholesterolemia. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia","volume":"173","author":"Civeira","year":"2004","journal-title":"Atherosclerosis"},{"key":"2020071614231287700_B2","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.gene.2014.09.020","article-title":"The history of autosomal recessive hypercholesterolemia (ARH). From clinical observations to gene identification","volume":"555","author":"Fellin","year":"2015","journal-title":"Gene"},{"key":"2020071614231287700_B3","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.amjcard.2008.06.056","article-title":"Comparison of genetic versus clinical diagnosis in familial hypercholesterolemia","volume":"102","author":"Civeira","year":"2008","journal-title":"Am J Cardiol"},{"key":"2020071614231287700_B4","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","article-title":"European Atherosclerosis Society Consensus Panel. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur Heart J"},{"key":"2020071614231287700_B5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1399-0004.2007.00915.x","article-title":"Genetic heterogeneity of autosomal dominant hypercholesterolemia","volume":"73","author":"Varret","year":"2008","journal-title":"Clin Genet"},{"key":"2020071614231287700_B6","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1139\/g06-147","article-title":"Genetic susceptibility to heart disease in Canada: lessons from patients with familial hypercholesterolemia","volume":"49","author":"Hegele","year":"2006","journal-title":"Genome"},{"key":"2020071614231287700_B7","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1161\/CIRCGENETICS.112.963587","article-title":"Low prevalence of mutations in known loci for autosomal dominant hypercholesterolemia in a multiethnic patient cohort","volume":"5","author":"Ahmad","year":"2012","journal-title":"Circ Cardiovasc Genet"},{"key":"2020071614231287700_B8","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1399-0004.2010.01485.x","article-title":"A presumptive new locus for autosomal dominant hypercholesterolemia mapping to 8q24.22","volume":"79","author":"Cenarro","year":"2011","journal-title":"Clin Genet"},{"key":"2020071614231287700_B9","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1161\/CIRCRESAHA.115.304660","article-title":"Mutations in STAP1 are associated with autosomal dominant hypercholesterolemia","volume":"115","author":"Fouchier","year":"2014","journal-title":"Circ Res"},{"key":"2020071614231287700_B10","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S0140-6736(12)62127-8","article-title":"Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study","volume":"381","author":"Talmud","year":"2013","journal-title":"Lancet"},{"key":"2020071614231287700_B11","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/00041433-199510000-00011","article-title":"Chylomicron remnants: hepatic receptors and metabolism","volume":"6","author":"Havel","year":"1995","journal-title":"Curr Opin Lipidol"},{"key":"2020071614231287700_B12","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1385\/MN:23:1:53","article-title":"Low-density lipoprotein receptor family: endocytosis and signal transduction","volume":"23","author":"Li","year":"2001","journal-title":"Mol Neurobiol"},{"key":"2020071614231287700_B13","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/S0022-2275(20)38060-3","article-title":"Studies of familial type III hyperlipoproteinemia using as a genetic marker the apoE phenotype E2\/2","volume":"23","author":"Breslow","year":"1982","journal-title":"J Lipid Res"},{"key":"2020071614231287700_B14","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0021-9150(95)06745-0","article-title":"Incomplete dominance of type III hyperlipoproteinemia is associated with the rare apolipoprotein E2 (Arg136\u2013&gt;Ser) variant in multigenerational pedigree studies","volume":"122","author":"Pocovi","year":"1996","journal-title":"Atherosclerosis"},{"key":"2020071614231287700_B15","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1172\/JCI118096","article-title":"Dominant expression of type III hyperlipoproteinemia. Pathophysiological insights derived from the structural and kinetic characteristics of ApoE-1 (Lys146\u2013&gt;Glu)","volume":"96","author":"Mann","year":"1995","journal-title":"J Clin Invest"},{"key":"2020071614231287700_B16","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1161\/01.ATV.17.5.865","article-title":"The apolipoprotein E2 (Arg145Cys) mutation causes autosomal dominant type III hyperlipoproteinemia with incomplete penetrance","volume":"17","author":"de Villiers","year":"1997","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2020071614231287700_B17","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.atherosclerosis.2012.03.011","article-title":"Apolipoprotein E gene mutations in subjects with mixed hyperlipidemia and a clinical diagnosis of familial combined hyperlipidemia","volume":"222","author":"Solanas-Barca","year":"2012","journal-title":"Atherosclerosis"},{"key":"2020071614231287700_B18","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/humu.22215","article-title":"Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation","volume":"34","author":"Marduel","year":"2013","journal-title":"Hum Mutat"},{"key":"2020071614231287700_B19","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.atherosclerosis.2013.09.007","article-title":"APOE p.Leu167del mutation in familial hypercholesterolemia","volume":"231","author":"Awan","year":"2013","journal-title":"Atherosclerosis"},{"key":"2020071614231287700_B20","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1194\/jlr.P023994","article-title":"Plasma levels of PCSK9 and phenotypic variability in familial hypercholesterolemia","volume":"53","author":"Huijgen","year":"2012","journal-title":"J Lipid Res"},{"key":"2020071614231287700_B21","first-page":"4354","article-title":"Familial splenomegaly: macrophage hypercatabolism of lipoproteins associated with apolipoprotein E mutation [apolipoprotein E (delta149 Leu)]","volume":"85","author":"Nguyen","year":"2000","journal-title":"Clin Endocrinol Metab"},{"key":"2020071614231287700_B22","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1038\/sj.ejhg.5201480","article-title":"Variable expressivity of the clinical and biochemical phenotype associated with the apolipoprotein E p.Leu149del mutation","volume":"13","author":"Faivre","year":"2005","journal-title":"Eur J Hum Genet"},{"key":"2020071614231287700_B23","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1373\/clinchem.2007.097139","article-title":"An unusual case of severe hypertriglyceridemia and splenomegaly","volume":"54","author":"Rahalkar","year":"2008","journal-title":"Clin Chem"},{"key":"2020071614231287700_B24","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.jacl.2013.09.003","article-title":"Inherited lipemic splenomegaly and the spectrum of apolipoprotein E p.Leu167del mutation phenotypic variation","volume":"7","author":"Okorodudu","year":"2013","journal-title":"J Clin Lipidol"},{"key":"2020071614231287700_B25","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1136\/jmedgenet-2014-102405","article-title":"Whole exome sequencing of familial hypercholesterolaemia patients negative for LDLR\/APOB\/PCSK9 mutations","volume":"51","author":"Futema","year":"2014","journal-title":"J Med Genet"},{"key":"2020071614231287700_B26","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1126\/science.3283935","article-title":"Apolipoprotein E: cholesterol transport protein with expanding role in cell biology","volume":"240","author":"Mahley","year":"1988","journal-title":"Science"},{"key":"2020071614231287700_B27","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1074\/jbc.275.4.2576","article-title":"Effect of arginine 172 on the binding of apolipoprotein E to the low density lipoprotein receptor","volume":"275","author":"Morrow","year":"2000","journal-title":"J Biol Chem"},{"key":"2020071614231287700_B28","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1111\/febs.12721","article-title":"LDL receptor\/lipoprotein recognition: endosomal weakening of ApoB and ApoE binding to the convex face of the LR5 repeat","volume":"281","author":"Mart\u00ednez-Oliv\u00e1n","year":"2014","journal-title":"FEBS J"},{"key":"2020071614231287700_B29","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1083\/jcb.115.6.1547","article-title":"The influence of particle size and multiple apoprotein E-receptor interactions on the endocytic targeting of beta-VLDL in mouse peritoneal macrophages","volume":"115","author":"Tabas","year":"1991","journal-title":"J Cell Biol"},{"key":"2020071614231287700_B30","doi-asserted-by":"crossref","first-page":"13452","DOI":"10.1074\/jbc.273.22.13452","article-title":"Differential cellular accumulation\/retention of apolipoprotein E mediated by cell surface heparan sulfate proteoglycans","volume":"273","author":"Ji","year":"1998","journal-title":"J Biol Chem"},{"key":"2020071614231287700_B31","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S1050-1738(00)00033-5","article-title":"The cell biology and physiologic relevance of apoE recycling","volume":"10","author":"Fazio","year":"2000","journal-title":"Trends Cardiovasc Med"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/101\/5\/2113\/10428951\/jcem2113.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/101\/5\/2113\/10428951\/jcem2113.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T01:38:41Z","timestamp":1655343521000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/101\/5\/2113\/2804803"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,1]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2015-3874","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,1]]}}}